| 1 |
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine
Open access |
11 May 2011 |
7,927 |
| 2 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al. · The Lancet
Open access |
5 Dec 2016 |
3,732 |
| 3 |
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Daniel J. Klionsky et al. · Autophagy
Open access2,930 authors |
2 Jan 2021 |
2,743 |
| 4 |
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine
|
9 Feb 2011 |
2,567 |
| 5 |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew Xiuxuan Zhu et al. · The Lancet Oncology
|
3 Jun 2018 |
2,555 |
| 6 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
2,026 |
| 7 |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al. · Journal of Clinical Oncology
|
2 Dec 2019 |
1,842 |
| 8 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew Xiuxuan Zhu et al. · The Lancet Oncology
|
18 Jan 2019 |
1,680 |
| 9 |
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al. · New England Journal of Medicine
Open access |
21 Apr 2021 |
1,671 |
| 10 |
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
Georgina Venetia Long et al. · New England Journal of Medicine
Open access |
10 Sep 2017 |
1,501 |
| 11 |
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al. · New England Journal of Medicine
Open access |
13 May 2015 |
1,457 |
| 12 |
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology
|
27 Nov 2019 |
1,226 |
| 13 |
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso et al. · Annals of Oncology
Open access |
23 May 2018 |
1,202 |
| 14 |
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn, Masafumi Ikeda, Andrew Xiuxuan Zhu et al. · Journal of Clinical Oncology
Open access |
27 Jul 2020 |
1,188 |
| 15 |
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al. · The Lancet Oncology
|
13 Dec 2021 |
1,119 |
| 16 |
Endoplasmic reticulum stress signalling – from basic mechanisms to clinical applications
Aitor Almanza et al. · FEBS Journal
Open access |
20 Jul 2018 |
1,050 |
| 17 |
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
Martin J. van den Bent, D Afra, Olivier De Witte et al. · The Lancet
|
20 Aug 2005 |
1,035 |
| 18 |
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Cynthia Lebeaupin, Déborah Vallée, Younis Hazari et al. · Journal of Hepatology
Open access |
26 Jun 2018 |
982 |
| 19 |
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Yau, T. (Thomas) et al. · Deposito Adademico Digital Universidad De Navarra (University of Navarra)
|
2022 |
954 |
| 20 |
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Arnaud Méjean et al. · New England Journal of Medicine
|
3 Jun 2018 |
954 |
| 21 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix, Jean‐Luc Raoul, Morris Sherman et al. · Journal of Hepatology
Open access |
19 Jun 2012 |
825 |
| 22 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Karim S. Fizazi et al. · The Lancet
Open access |
Apr 2022 |
823 |
| 23 |
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Alain Ravaud et al. · New England Journal of Medicine
|
10 Oct 2016 |
791 |
| 24 |
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies, Philippe Saïag, Caroline Robert et al. · The Lancet Oncology
Open access |
4 Jun 2017 |
785 |
| 25 |
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip James Johnson et al. · Journal of Clinical Oncology
|
27 Aug 2013 |
780 |
| 26 |
Genomic characterization of metastatic breast cancers
François Bertucci et al. · Nature
|
May 2019 |
755 |
| 27 |
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwénaëlle Gravis et al. · The Lancet Oncology
|
8 Jan 2013 |
747 |
| 28 |
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al. · New England Journal of Medicine
Open access |
11 Dec 2014 |
736 |
| 29 |
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, John A. Bridgewater, Julien Edeline et al. · Annals of Oncology
Open access |
10 Nov 2022 |
716 |
| 30 |
Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
Jean-Claude Horiot, René Le Fur, T. Nguyen et al. · Radiotherapy and Oncology
|
Dec 1992 |
684 |
| 31 |
Endoplasmic Reticulum Stress and the Hallmarks of Cancer
Hery Urra, Estefanie Dufey, Tony Avril et al. · Trends in cancer
ReviewOpen access |
30 Apr 2016 |
666 |
| 32 |
Getting RIDD of RNA: IRE1 in cell fate regulation
M. Maurel, Éric Chevet, Jan H. Tavernier et al. · Trends in Biochemical Sciences
Review |
22 Mar 2014 |
657 |
| 33 |
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Thomas C. C. Yau, J.W. Park, Richard S. Finn et al. · Annals of Oncology
Open access |
Oct 2019 |
650 |
| 34 |
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
Étienne Garin et al. · The Lancet. Gastroenterology & hepatology
Open access |
6 Nov 2020 |
640 |
| 35 |
A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus
É. Le Prisé, Pierre Luc Etienne, Bernard Meunier et al. · Cancer
Open access |
Apr 1994 |
623 |
| 36 |
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
Julien Edeline et al. · Journal of Clinical Oncology
|
Feb 2019 |
543 |
| 37 |
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
Jean‐Luc Raoul, Bruno Sangro, Alejandro Forner et al. · Cancer Treatment Reviews
|
19 Aug 2010 |
535 |
| 38 |
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto et al. · Nature
100 authors |
18 Oct 2011 |
529 |
| 39 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio M. P. Omuro et al. · Neuro-Oncology
Open access |
14 Apr 2022 |
522 |
| 40 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert et al. · The Lancet Oncology
Open access |
29 Sep 2016 |
504 |
| 41 |
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Leisha A. Emens, Sylvia Adams, Carlos H. Barrios et al. · Annals of Oncology
Open access |
Jul 2021 |
492 |
| 42 |
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology
|
21 Nov 2015 |
465 |
| 43 |
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
Rachna T. Shroff, Erin B. Kennedy, Melinda Bachini et al. · Journal of Clinical Oncology
|
11 Mar 2019 |
459 |
| 44 |
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial
V. Beckendorf, Stephane Gilles Guerif, É. Le Prisé et al. · International Journal of Radiation Oncology*Biology*Physics
|
15 Dec 2010 |
459 |
| 45 |
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep Maria Llovet et al. · The Lancet Oncology
Open access209 authors |
28 Nov 2023 |
455 |
| 46 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology
|
17 Feb 2014 |
455 |
| 47 |
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Hope S. Rugo, Richard S. Finn, Veronique C Dieras et al. · Breast Cancer Research and Treatment
Open access |
10 Jan 2019 |
452 |
| 48 |
Genome-wide association studies identify four ER negative–specific breast cancer risk loci
The Gene ENvironmental Interaction and breast CAncer (GENICA) Network et al. · Nature Genetics
Open access274 authors |
27 Mar 2013 |
422 |
| 49 |
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice André, Thomas Bachelot, Frédéric Commo et al. · The Lancet Oncology
|
6 Feb 2014 |
418 |
| 50 |
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka et al. · The Lancet Oncology
Open access |
19 May 2014 |
417 |